p16(MTS1/CDK4I) mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx

P Jares, PL Fernandez, A Nadal, M Cazorla, L Hernandez, M Pinyol, S Hernandez, J Traserra, A Cardesa, E Campo

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We have examined the presence of p16(MTS1/CDK4I) gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene amplification and overexpression. pRb expression was also examined by immunohistochemistry. p16(MTS1/CDK4I) mutations were found in 10/46 (22%) carcinomas and hypermethylation in 2/31 (7%). Loss of heterozygosity at 9p21-23 was found in 24 out of 42 (57%) carcinomas examined. All p16(MTS1/CDK4I) mutated cases and the two hypermethylated carcinomas showed 9p21-23 loss of heterozygosity. The loss of heterozygosity correlated with advanced local invasion (P = 0.0045), lymph node metastases (P = 0.0326), stage IV of the tumors (P = 0.0058), and existence of cyclin D1 amplification/overexpression (P <0.03). Only one out of 37 carcinomas was negative for pRb expression. No alterations in p16 gene or 9p21-23 loss of heterozygosity were detected in this case. These findings indicate that p16(MTS1/CDK4I) is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a significant subset of squamous cell carcinomas of larynx. Since 9p21-233 loss of heterozygosity was more frequently detected than p16(MTS1/CDK4I) mutations, and mutated carcinomas invariably had loss of heterozygosity, allelic losses probably precede the p16(MTS1/CDK4I) mutations. Their association with cyclin D1 deregulation in advanced carcinomas could indicate a possible cooperative effect in the progression of these neoplasms.

Original languageEnglish
Pages (from-to)1445-1453
Number of pages9
JournalOncogene. PMID: 17873908.
Volume15
Issue number12
DOIs
Publication statusPublished - 18 Sep 1997

Keywords

  • p16(MTS1/CDK4I)
  • LOH 9p21-23
  • larynx
  • squamous cell carcinoma
  • KINASE-4 INHIBITOR GENE
  • CYCLIN D1 FUNCTION
  • HUMAN CANCERS
  • SOMATIC MUTATIONS
  • NONSMALL CELL
  • GEL-ELECTROPHORESIS
  • ALTERED EXPRESSION
  • PRIMARY TUMORS
  • LUNG CANCERS
  • CDKN2 GENE

Cite this

Jares, P., Fernandez, PL., Nadal, A., Cazorla, M., Hernandez, L., Pinyol, M., Hernandez, S., Traserra, J., Cardesa, A., & Campo, E. (1997). p16(MTS1/CDK4I) mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene. PMID: 17873908., 15(12), 1445-1453. https://doi.org/10.1038/sj.onc.1201309